RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
 Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Health Channel

subscribe to Health newsletter
Health

   EMAIL   |   PRINT
US approves inhaler for adult diabetic patients

Jan 31, 2006 - 6:48:00 PM , Reviewed by: Priya Saxena
The FDA, which approved it Friday, said the safety and efficacy of Exubera, the first new delivery system for insulin since it was developed some 80 years ago, have been studied in approximately 2,500 adult patients with type 1 and type 2 diabetes.

 
[RxPG] The US Food and Drug Administration (FDA) has approved an inhaler that could instantly regulate blood sugar level, bringing relief to the adults suffering from diabetes.

The hand-held Exubera inhaler is a rapid-acting, dry powder human insulin that is inhaled through the mouth prior to eating.

It weighs four ounces and, when closed, is about the size of an eyeglass case. The unique inhaler produces in its chamber a cloud of insulin powder, which is designed to pass rapidly into the bloodstream to regulate the body's blood sugar levels, reported health portal MedPage Today.

The FDA, which approved it Friday, said the safety and efficacy of Exubera, the first new delivery system for insulin since it was developed some 80 years ago, have been studied in approximately 2,500 adult patients with type 1 and type 2 diabetes.

In clinical studies, peak insulin levels were achieved at 49 minutes (range 30 to 90 minutes) with Exubera inhaled insulin, compared to 105 minutes (range 60 to 240 minutes) for short-acting insulin, it said.

However smokers or those who quit smoking in the past six months should not use Exubera, the FDA said. It was also contraindicated for patients with asthma, bronchitis, or emphysema.



Publication: Indo-Asian News Service

Advertise in this space for $10 per month. Contact us today.


Related Health News


Subscribe to Health Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)